Abstract: An oral care formulation and method for removing tartar and plaque from the teeth, gums, and oral cavity is disclosed. The oral care formulation can take the form of a toothpaste, gel, wash, rinse, soak, spray, chewing gum, dental floss, or other suitable delivery system, containing a therapeutically effective amount of dimethyl isosorbide (DMI) (or equivalent or analog thereof) and chlorine dioxide (ClO2) for removal of tartar and plaque.
Abstract: The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm.
Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
June 2, 2020
Assignee:
Nitto Denko Corporation
Inventors:
Yoshiro Niitsu, Joseph E. Payne, John A. Gaudette, Zheng Hou, Victor Knopov, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Violetta Akopian
Abstract: Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
June 2, 2020
Assignee:
The Johns Hopkins University
Inventors:
Justin Hanes, Katharina Maisel, Laura Ensign, Richard Cone
Abstract: Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.
Type:
Grant
Filed:
January 20, 2016
Date of Patent:
June 2, 2020
Assignees:
InCarda Therapeutics, Inc., The Regents of the University of California
Abstract: The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.
Abstract: Antimicrobial compositions and methods for depositing or coating the antimicrobial or antibacterial compositions on a substrate to prevent microbial adhesion are provided. The antimicrobial composition may include a cationic polymer having a poly-allylamine backbone. A portion of the poly-allylamine backbone may be functionalized with at least one of a guanidine functional group and a biguanide functional group.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
May 19, 2020
Assignee:
Colgate-Palmolive Company
Inventors:
Carl Myers, Carlo Daep, Lynette Zaidel, James Masters, Russell Composto, Hyun-Su Lee
Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a drug in a dissolved state, an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase, and a release rate of the drug from each of the liposomes is 10%/24 hr to 70%/24 hr in blood plasma at 37° C.; and a method for producing the same.
Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
Type:
Grant
Filed:
October 22, 2014
Date of Patent:
May 5, 2020
Assignee:
Lipella Pharmaceuticals, Inc.
Inventors:
Jonathan H. Kaufman, Michael B. Chancellor
Abstract: Particulate solid composite material for purifying nucleic acids containing magnetic nanoparticles embedded in a carrier matrix based on at least one polymer that is obtained by polyaddition of a) at least one isocyanate-reactive monomer A, selected from compounds containing at least two functional groups, each having at least one Zerewitinoff-reactive hydrogen atom, and in addition to these at least two functional groups, carry at least one anionic or potentially anionic residue, preferably selected from the group consisting of carboxylate, sulfonate or combinations thereof, with b) at least one polyisocyanate monomer B with the provisio that said polyaddition occurs in the presence of magnetic nanoparticles, is particularly suitable as carrier material for purification of nucleic acids. Said composite material is easy to prepare, is stable, and magnetic and has outstanding application properties in the bind-wash-elute purification of nucleic acids using magnetic separation.
Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
Abstract: A bio control surface (100) comprising a substrate (5) and a first plurality of discrete, spaced-apart particles (1) disposed on the substrate (5) and a second plurality of discrete, spaced-apart particles (6) disposed on the substrate (5), wherein the first (1) and second (6) pluralities of discrete, spaced-apart particles are formed from species having different chemical and/or electrical properties. An intermediate layer (4) may be interposed between the particles (1, 6) and the substrate (5). The bio control surface (100) can be activated by exposure to particular conditions, which cause the first (1) and second (6) pluralities of particles to adopt different potentials (+, ?), such that flow of charge, heat, ions etc. can be used to neutralise or kill bacteria or microorganisms resident on the surface (100).
Type:
Grant
Filed:
April 1, 2014
Date of Patent:
April 14, 2020
Assignee:
Gencoa Ltd.
Inventors:
Victor Bellido-Gonzalez, Dermot Patrick Monaghan
Abstract: The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
April 7, 2020
Assignee:
The Regents of the University of California
Inventors:
Liangfang Zhang, Zhiqing Pang, Ronnie H. Fang, Che-Ming Jack Hu
Abstract: This invention relates to novel nanocompounds that are cytotoxic to tumor cells when combined with ultraviolet light, the nanocompounds comprising multilayered carbon nanotubes with anatase-phase titanium dioxide or anatase-phase titanium dioxide and folate. The invention also relates to a composition containing said nanocompounds and to a method for the treatment of cancer; comprising the administration of said composition in co-treatment with UV radiation. The invention further relates to a method for the synthesis of the nano-compounds.
Type:
Grant
Filed:
February 17, 2015
Date of Patent:
March 31, 2020
Assignee:
Universidad del Valle
Inventors:
Rubén Jesús Camargo Amado, José Oscar Gutiérrez Montes, Mónica Jimena Basante Romo, William David Criollo Gómez
Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
March 24, 2020
Assignee:
University of Pittburgh—Of the Commonwealth System of Higher Education
Inventors:
Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
Abstract: The present invention provides a water continuous dispersion of nanoparticles. The water continuous dispersion includes: one or more aromatic amide anesthetic compounds; one or more polyethoxylated high HLB surfactants; one or more low HLB surfactants; one or more oils, wherein one or more nanoparticles of a dispersed phase include a lipid bilayer, and wherein ratio of oil to surfactant is between about 0.12:1 to about 3.5:1. Methods of preparing various water continuous dispersion of nanoparticles are also provided.
Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
March 10, 2020
Assignee:
Indiana University Research and Technology Corporation
Inventors:
Jeffrey A. Kline, Nathan J. Alves, Daren M. Beam
Abstract: Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
Abstract: Disclosed herein are iron oxide nanoparticles prepared through high-temperature thermal decomposition of an Fe3+ precursor and an M+ or M2+ (M=Li, Na, K, Mg, and Ca) precursor in an oxygen atmosphere. The iron oxide nanoparticles are nanoparticles, in which an alkali metal or alkali earth metal is doped into an Fe vacancy site of ?-Fe2O3, and generate explosive heat even in a biocompatible low AC magnetic field. Through both in vitro and in vivo tests, it was proven that cancer cells could be killed by performing low-frequency hyperthermia using the iron oxide nanoparticles set forth above.
Abstract: The present invention provides a method of preparing highly stable microcapsule powders or microparticles containing a fat-soluble nutrient having multiple double bonds.
Type:
Grant
Filed:
October 12, 2015
Date of Patent:
February 25, 2020
Assignee:
Zhejiang Medicine Co., Ltd
Inventors:
Xinde Xu, Di Zhou, Lihua Zhang, Bin Shao